Related Experiment Videos
[Inhaled nitric oxide therapy in preterm infants]
T Hoehn1, M F Krause, C Bührer
1Klinik für Neonatologie, Charité, Virchow-Klinikum, Humboldt-Universität, Berlin. thomas.hoehn@charite.de
Klinische Padiatrie
|May 17, 2000
Summary
Inhaled nitric oxide (iNO) is a standard treatment for persistent pulmonary hypertension of the newborn (PPHN). For premature infants, iNO does not increase the risk of intraventricular hemorrhage (IVH).
Area of Science:
- Neonatology
- Pediatric Critical Care
- Pulmonary Medicine
Context:
- Persistent pulmonary hypertension of the newborn (PPHN) is a serious condition in neonates.
- Inhaled nitric oxide (iNO) is an established treatment for PPHN in term infants.
- The use and safety of iNO in preterm infants remain areas of investigation due to concerns about intraventricular hemorrhage (IVH).
Purpose:
- To evaluate the safety and efficacy of inhaled nitric oxide (iNO) in the treatment of persistent pulmonary hypertension of the newborn (PPHN), specifically in preterm infants.
- To address the controversial discussion regarding the risk of intraventricular hemorrhage (IVH) during iNO therapy in premature neonates.
Summary:
- Randomized controlled trials indicate that inhaled nitric oxide (iNO) is an established treatment for PPHN in neonatology.
- While nitric oxide's effect on platelet aggregation raises concerns about intraventricular hemorrhage (IVH) in preterm infants, recent large studies show no increased incidence of IVH with iNO therapy.
- Existing studies report variable IVH incidences, necessitating further research.
Impact:
- Clinical application of iNO in preterm infants is not associated with an increased incidence of intraventricular hemorrhage (IVH).
- Further randomized controlled trials are crucial to define the future role and indications of iNO therapy in preterm neonates.
- This research contributes to optimizing PPHN management in vulnerable preterm populations.